CY1121457T1 - Πολυλειτουργικα αλληλομορφα - Google Patents
Πολυλειτουργικα αλληλομορφαInfo
- Publication number
- CY1121457T1 CY1121457T1 CY20191100345T CY191100345T CY1121457T1 CY 1121457 T1 CY1121457 T1 CY 1121457T1 CY 20191100345 T CY20191100345 T CY 20191100345T CY 191100345 T CY191100345 T CY 191100345T CY 1121457 T1 CY1121457 T1 CY 1121457T1
- Authority
- CY
- Cyprus
- Prior art keywords
- allele
- coin
- alleles
- zero
- action
- Prior art date
Links
- 108700028369 Alleles Proteins 0.000 abstract 12
- 230000004913 activation Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 206010010356 Congenital anomaly Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 238000005215 recombination Methods 0.000 abstract 1
- 230000006798 recombination Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/20—Animal model comprising regulated expression system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/60—Vectors containing traps for, e.g. exons, promoters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Παρέχονται κατασκευάσματα νουκλεϊκών οξέων και μέθοδοι που θέτουν τροποποιήσεις σε ένα γονιδίωμα, όπου οι τροποποιήσεις περιλαμβάνουν μηδενικά αλληλόμορφα, ελεγχόμενα αλληλόμορφα και μηδενικά αλληλόμορφα που περιλαμβάνουν COIN. Παρέχονται πολυλειτουργικά αλληλόμορφα (MFA), καθώς και μέθοδοι για την παρασκευή τους, οι οποίες παρέχουν τη δυνατότητα σε μια μοναδική στόχευση να εισαχθεί ένα αλληλόμορφο που μπορεί να χρησιμοποιηθεί για να παράγει ένα μηδενικό αλληλόμορφο, ένα ελεγχόμενο αλληλόμορφο ή ένα αλληλόμορφο που είναι μηδενικό αλληλόμορφο και που περιλαμβάνει περαιτέρω ένα COIN. Τα MFA περιλαμβάνουν ζεύγη θέσεων αναγνώρισης της συγγενούς ανασυνδυάσης, μια αλληλουχία ενεργοποίησης ή/και μια κασέτα επιλογής φαρμάκου, καθώς και μια νουκλεοτιδική αλληλουχία ενδιαφέροντος και ένα COIN, όπου κατά τη δράση μιας ανασυνδυάσης σχηματίζεται ένα ελεγχόμενο αλληλόμορφο με ένα COIN. Σε μια περαιτέρω υλοποίηση, η δράση μιας δεύτερης ανασυνδυάσης σχηματίζει ένα αλληλόμορφο που περιέχει μόνο ένα COIN με νοηματικό προσανατολισμό. Σε μια περαιτέρω υλοποίηση, η δράση μιας τρίτης ανασυνδυάσης σχηματίζει ένα αλληλόμορφο που περιέχει μόνο την αλληλουχία ενεργοποίησης με νοηματικό προσανατολισμό.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25607809P | 2009-10-29 | 2009-10-29 | |
| PCT/US2010/054654 WO2011059799A1 (en) | 2009-10-29 | 2010-10-29 | Multifunctional alleles |
| EP10774391.6A EP2494047B1 (en) | 2009-10-29 | 2010-10-29 | Multifunctional alleles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1121457T1 true CY1121457T1 (el) | 2020-05-29 |
Family
ID=43244777
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171100118T CY1118659T1 (el) | 2009-10-29 | 2017-01-26 | Πολυλειτουργικα αλληλομορφα |
| CY20191100345T CY1121457T1 (el) | 2009-10-29 | 2019-03-26 | Πολυλειτουργικα αλληλομορφα |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171100118T CY1118659T1 (el) | 2009-10-29 | 2017-01-26 | Πολυλειτουργικα αλληλομορφα |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20110104799A1 (el) |
| EP (2) | EP2494047B1 (el) |
| JP (3) | JP5908405B2 (el) |
| CN (2) | CN102666854B (el) |
| AU (1) | AU2010319894B2 (el) |
| CA (1) | CA2779858C (el) |
| CY (2) | CY1118659T1 (el) |
| DK (2) | DK2494047T3 (el) |
| ES (2) | ES2716981T3 (el) |
| PL (2) | PL2494047T3 (el) |
| PT (2) | PT3147362T (el) |
| TR (1) | TR201903376T4 (el) |
| WO (1) | WO2011059799A1 (el) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR201903376T4 (tr) | 2009-10-29 | 2019-04-22 | Regeneron Pharma | Çok fonksiyonlu alleller. |
| SG11201406547YA (en) | 2012-04-25 | 2014-11-27 | Regeneron Pharma | Nuclease-mediated targeting with large targeting vectors |
| US9510569B2 (en) * | 2013-03-13 | 2016-12-06 | Regeneron Pharmaceuticals, Inc. | Genetically modified mouse with an inducible Acvr1 gene with a mutant R206H exon 5 that has ectopic bone formation |
| DK2986729T3 (en) | 2013-04-16 | 2018-10-29 | Regeneron Pharma | TARGETED MODIFICATION OF ROOT THROUGH |
| DK3178928T3 (da) * | 2013-08-07 | 2020-08-24 | Regeneron Pharma | Pint-knockout-mus med en præmatur, aldersassocieret fænotype |
| RU2685914C1 (ru) | 2013-12-11 | 2019-04-23 | Регенерон Фармасьютикалс, Инк. | Способы и композиции для направленной модификации генома |
| EP3460063B1 (en) | 2013-12-11 | 2024-03-13 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for the targeted modification of a genome |
| KR102374379B1 (ko) | 2014-06-06 | 2022-03-17 | 리제너론 파마슈티칼스 인코포레이티드 | 표적화된 좌를 변형시키는 방법 및 조성물 |
| EP3155099B1 (en) | 2014-06-23 | 2018-03-21 | Regeneron Pharmaceuticals, Inc. | Nuclease-mediated dna assembly |
| ES2901074T3 (es) | 2014-06-26 | 2022-03-21 | Regeneron Pharma | Métodos y composiciones para modificaciones genéticas objetivo y métodos de uso |
| MX2017004890A (es) | 2014-10-15 | 2018-02-12 | Regeneron Pharma | Metodos y composiciones para la generación o el mantenimiento de células pluripotentes. |
| NZ731962A (en) | 2014-11-21 | 2022-07-01 | Regeneron Pharma | Methods and compositions for targeted genetic modification using paired guide rnas |
| MX2017008190A (es) | 2014-12-19 | 2018-03-23 | Regeneron Pharma | Metodos y composiciones para la modificacion genetica dirigida a traves de direccionamiento multiple de una sola etapa. |
| EP3270688B1 (en) | 2015-03-16 | 2020-08-12 | Regeneron Pharmaceuticals, Inc. | Non-human animal exhibiting diminished upper and lower motor neuron function and sensory perception |
| WO2017180669A1 (en) * | 2016-04-11 | 2017-10-19 | Applied Stemcell, Inc. | Site-specific integration of transgenes |
| MX2018014172A (es) | 2016-05-20 | 2019-08-22 | Regeneron Pharma | Métodos para romper la tolerancia inmunológica usando múltiples arn guías. |
| CN109803530A (zh) | 2016-07-29 | 2019-05-24 | 瑞泽恩制药公司 | 包含引起c-截短的原纤维蛋白-1表达的突变的小鼠 |
| CN107779462B (zh) * | 2016-08-29 | 2021-06-04 | 中国科学院分子细胞科学卓越创新中心 | 双同源重组谱系示踪技术 |
| WO2018096356A1 (en) * | 2016-11-28 | 2018-05-31 | Horizon Discovery Limited | Methods for conditional gene knock-out |
| RU2019126483A (ru) | 2017-01-23 | 2021-02-24 | Ридженерон Фармасьютикалз, Инк. | Варианты 17-бета-гидроксистероиддегидрогеназы 13 (hsd17b13) и их применение |
| SG11201911886PA (en) | 2017-06-27 | 2020-01-30 | Regeneron Pharma | Non-human animals comprising a humanized asgr1 locus |
| US20190098879A1 (en) | 2017-09-29 | 2019-04-04 | Regeneron Pharmaceuticals, Inc. | Non-Human Animals Comprising A Humanized TTR Locus And Methods Of Use |
| KR102444458B1 (ko) | 2017-11-10 | 2022-09-19 | 리제너론 파마슈티칼스 인코포레이티드 | Slc30a8 돌연변이를 포함하는 비인간 동물 및 사용 방법 |
| EP4299732A3 (en) | 2017-11-30 | 2024-03-27 | Regeneron Pharmaceuticals, Inc. | Rats comprising a humanized trkb locus |
| MX2020013545A (es) | 2018-06-13 | 2021-02-26 | Regeneron Pharma | Modelo en roedores de fibrodisplasia osificante progresiva. |
| EP3732291A1 (en) | 2018-12-20 | 2020-11-04 | Regeneron Pharmaceuticals, Inc. | Nuclease-mediated repeat expansion |
| AU2020256225A1 (en) | 2019-04-03 | 2021-09-02 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for insertion of antibody coding sequences into a safe harbor locus |
| CA3133360A1 (en) | 2019-04-04 | 2020-10-08 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized coagulation factor 12 locus |
| CN113874510A (zh) | 2019-06-04 | 2021-12-31 | 瑞泽恩制药公司 | 包括具有β滑移突变的人源化TTR基因座的非人动物和使用方法 |
| KR20220017939A (ko) | 2019-06-07 | 2022-02-14 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화 알부민 좌위를 포함하는 비-인간 동물 |
| AU2020294880B2 (en) * | 2019-06-19 | 2024-05-02 | F. Hoffmann-La Roche Ag | Method for the generation of a protein expressing cell by targeted integration using Cre mRNA |
| CN114746125A (zh) | 2019-11-08 | 2022-07-12 | 瑞泽恩制药公司 | 用于x连锁青少年型视网膜劈裂症疗法的crispr和aav策略 |
| WO2021108363A1 (en) | 2019-11-25 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Crispr/cas-mediated upregulation of humanized ttr allele |
| CN115175559A (zh) | 2020-01-28 | 2022-10-11 | 瑞泽恩制药公司 | 包含人源化pnpla3基因座的非人动物及其使用方法 |
| US20230081547A1 (en) | 2020-02-07 | 2023-03-16 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized klkb1 locus and methods of use |
| WO2021195079A1 (en) | 2020-03-23 | 2021-09-30 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use |
| WO2021263146A2 (en) | 2020-06-26 | 2021-12-30 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ace2 locus |
| KR20230119130A (ko) | 2020-12-14 | 2023-08-16 | 리제너론 파마슈티칼스 인코포레이티드 | 인히빈 서브유닛 베타 e(inhbe) 억제제로 대사 장애 및 심혈관 질환을 치료하는 방법 |
| US20230293727A1 (en) | 2021-10-26 | 2023-09-21 | Regeneron Pharmaceuticals, Inc. | Overexpression of lemd2, lemd3, or chmp7 as a therapeutic modality for tauopathy |
| WO2023077053A2 (en) | 2021-10-28 | 2023-05-04 | Regeneron Pharmaceuticals, Inc. | Crispr/cas-related methods and compositions for knocking out c5 |
| WO2023108047A1 (en) | 2021-12-08 | 2023-06-15 | Regeneron Pharmaceuticals, Inc. | Mutant myocilin disease model and uses thereof |
| WO2023122506A1 (en) | 2021-12-20 | 2023-06-29 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising humanized ace2 and tmprss loci |
| WO2023150798A1 (en) | 2022-02-07 | 2023-08-10 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for defining optimal treatment timeframes in lysosomal disease |
| WO2023220603A1 (en) | 2022-05-09 | 2023-11-16 | Regeneron Pharmaceuticals, Inc. | Vectors and methods for in vivo antibody production |
| WO2023220697A1 (en) * | 2022-05-12 | 2023-11-16 | Memorial Sloan-Kettering Cancer Center | Inducible recombinase systems |
| WO2023235725A2 (en) | 2022-05-31 | 2023-12-07 | Regeneron Pharmaceuticals, Inc. | Crispr-based therapeutics for c9orf72 repeat expansion disease |
| JP2024021835A (ja) * | 2022-08-04 | 2024-02-16 | 株式会社豊田中央研究所 | 相同組換え方法 |
| WO2024031053A1 (en) | 2022-08-05 | 2024-02-08 | Regeneron Pharmaceuticals, Inc. | Aggregation-resistant variants of tdp-43 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1092768A1 (en) * | 1999-10-16 | 2001-04-18 | ARTEMIS Pharmaceuticals GmbH | Conditional gene trapping construct for the disruption of genes |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| AU2002219841A1 (en) * | 2000-11-16 | 2002-05-27 | Cornell Research Foundation Inc. | Vectors for conditional gene inactivation |
| US7074611B2 (en) | 2001-04-27 | 2006-07-11 | Gie-Cerbn, Centre Europeen De Recherche En Biologie Et En Medecine (Gie) | Method for the stable inversion of DNA sequence by site-specific recombination and DNA vectors and transgenic cells thereof |
| US7473557B2 (en) | 2001-06-06 | 2009-01-06 | Regeneron Pharmaceuticals, Inc. | Method for targeting transcriptionally active loci |
| WO2005001087A2 (en) * | 2003-06-11 | 2005-01-06 | Regeneron Pharmaceuticals, Inc. | Methods of modifying genes in eukaryotic cells |
| US7582741B2 (en) * | 2004-07-26 | 2009-09-01 | University Of Massachusetts | Conditional disruption of dicer1 in cell lines and non-human mammals |
| EP1662005A1 (en) * | 2004-11-26 | 2006-05-31 | FrankGen Biotechnologie AG | Enhancer-containing gene trap vectors for random and targeted gene trapping |
| ATE497541T1 (de) | 2004-11-26 | 2011-02-15 | Frankgen Biotechnologie Ag | Gen-fallen-kassette für eine gerichtete und ungerichtete konditionelle geninaktivierung |
| TR201903376T4 (tr) | 2009-10-29 | 2019-04-22 | Regeneron Pharma | Çok fonksiyonlu alleller. |
-
2010
- 2010-10-29 TR TR2019/03376T patent/TR201903376T4/tr unknown
- 2010-10-29 US US12/915,447 patent/US20110104799A1/en not_active Abandoned
- 2010-10-29 ES ES16196614T patent/ES2716981T3/es active Active
- 2010-10-29 WO PCT/US2010/054654 patent/WO2011059799A1/en active Application Filing
- 2010-10-29 PL PL10774391T patent/PL2494047T3/pl unknown
- 2010-10-29 EP EP10774391.6A patent/EP2494047B1/en active Active
- 2010-10-29 ES ES10774391.6T patent/ES2613662T3/es active Active
- 2010-10-29 DK DK10774391.6T patent/DK2494047T3/en active
- 2010-10-29 PT PT16196614T patent/PT3147362T/pt unknown
- 2010-10-29 PL PL16196614T patent/PL3147362T3/pl unknown
- 2010-10-29 JP JP2012537099A patent/JP5908405B2/ja active Active
- 2010-10-29 CN CN201080056458.9A patent/CN102666854B/zh active Active
- 2010-10-29 CA CA2779858A patent/CA2779858C/en active Active
- 2010-10-29 DK DK16196614.8T patent/DK3147362T3/en active
- 2010-10-29 EP EP16196614.8A patent/EP3147362B1/en active Active
- 2010-10-29 PT PT107743916T patent/PT2494047T/pt unknown
- 2010-10-29 AU AU2010319894A patent/AU2010319894B2/en active Active
- 2010-10-29 CN CN201610565668.XA patent/CN106191126B/zh active Active
-
2013
- 2013-07-12 US US13/940,609 patent/US10392633B2/en active Active
-
2016
- 2016-02-01 JP JP2016017198A patent/JP6085696B2/ja active Active
- 2016-07-28 JP JP2016148272A patent/JP6333316B2/ja active Active
-
2017
- 2017-01-26 CY CY20171100118T patent/CY1118659T1/el unknown
-
2019
- 2019-03-26 CY CY20191100345T patent/CY1121457T1/el unknown
- 2019-07-01 US US16/459,236 patent/US11319557B2/en active Active
-
2022
- 2022-04-01 US US17/712,003 patent/US20220220510A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121457T1 (el) | Πολυλειτουργικα αλληλομορφα | |
| CY1121738T1 (el) | Μεθοδοι και συνθεσεις για στοχευμενη γενετικη τροποποιηση χρησιμοποιωντας συζευγμενα rna-οδηγους | |
| TR201904022T4 (tr) | Konakçı hücre modifikasyon yöntemleri. | |
| CY1120291T1 (el) | Μεθοδοι και συνθεσεις για κατευθυνομενη απο rna τροποποιηση dna στοχου και για κατευθυνομενη απο rna ρυθμιση της μεταγραφης | |
| EA201291024A1 (ru) | Композиции эндорибонуклеаз и способы их использования | |
| CY1122386T1 (el) | Χιμαιρικος υποδοχεας αντιγονων και μεθοδοι χρησης εξ αυτου | |
| CY1123831T1 (el) | Γενετικως τροποποιημενοι ποντικοι υποδοχεα τ κυτταρων | |
| CY1123774T1 (el) | Στελεχη shigella me υπερφυσαλιδωση | |
| CY1120272T1 (el) | ΠΑΡΟΧΗ mRNA ΓΙΑ ΤΗΝ ΑΥΞΗΣΗ ΠΡΩΤΕΪΝΩΝ ΚΑΙ ΕΝΖΥΜΩΝ ΣΕ ΑΝΘΡΩΠΙΝΕΣ ΓΕΝΕΤΙΚΕΣ ΑΣΘΕΝΕΙΕΣ | |
| NZ759895A (en) | Single cell whole genome libraries for methylation sequencing | |
| WO2014186585A3 (en) | Methods and compositions for treatment of a genetic condition | |
| CA2884084C (en) | Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks | |
| WO2014022702A3 (en) | Methods and compositions for controlling gene expression by rna processing | |
| MX338068B (es) | Polipeptidos que tienen actividad de glucoamilasa y polinucleotidos que codifican los mismos. | |
| MX2022001187A (es) | Método para determinar la secuencia de un ácido nucleico usando luminiscencia resuelta por tiempo. | |
| EP4261828A3 (en) | Methods and processes for non-invasive assessment of genetic variations | |
| WO2010127304A3 (en) | Sequencing methods | |
| EA201100225A1 (ru) | Новые регуляторные элементы | |
| MX2016004575A (es) | Metodos de modificacion de celulas huespedes. | |
| AR098300A1 (es) | Locus óptimos de la soja | |
| EA201691664A1 (ru) | МУТИРОВАННЫЕ ГЕНЫ СИНТАЗЫ АЦЕТОГИДРОКСИКИСЛОТ В Brassica | |
| AR053066A1 (es) | Arabinofuranosidasas | |
| MX2012006096A (es) | Polipeptidos que tienen actividad glucoamilasa y polinucleotidos que codifican para los mismos. | |
| BR112019008675A2 (pt) | roedor, célula isolada de roedor, e, métodos de produção de um roedor e de um anticorpo em um roedor. | |
| NZ595626A (en) | Wood and cell wall gene microarray |